Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;

Published byAlp Niazi Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;"— Presentation transcript:

1 Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis; PCR, polymerase chain reaction; INH, isoniazid; RFP, rifampin; CXR, chest X ray; IPM, imipenem; LVX, levofloxacin; MXF, moxifloxacin; AMK, amikacin; KAN, kanamycin; EMB, ethambutol; CCS, cycloserine; PTH, prothionamide; DMS, dexamethasone; LZD, linezolid; HD, Hospital day. Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis; PCR, polymerase chain reaction; INH, isoniazid; RFP, rifampin; CXR, chest X ray; IPM, imipenem; LVX, levofloxacin; MXF, moxifloxacin; AMK, amikacin; KAN, kanamycin; EMB, ethambutol; CCS, cycloserine. . . Infect Chemother Mar;48(1):

Download ppt "Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;"

Similar presentations

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.
TREATMENT OF TUBERCULOSIS, 2003

TREATMENT OF TUBERCULOSIS, 2003
Second-line Anti-TB drugs

Second-line Anti-TB drugs
Tuberculosis Evaluation in the Underserved Community John W. Wilson, MD Division of Infectious Diseases Mayo Clinic, Rochester.

Tuberculosis Evaluation in the Underserved Community John W. Wilson, MD Division of Infectious Diseases Mayo Clinic, Rochester.
‘Resistant infections’ 22.03.13 Dr Julian Sutton Consultant in Infectious Diseases & Medical Microbiology.

‘Resistant infections’ Dr Julian Sutton Consultant in Infectious Diseases & Medical Microbiology.
Sheboygan County 2013 Sandy Muesegades, RN – Public Health Nurse.

Sheboygan County 2013 Sandy Muesegades, RN – Public Health Nurse.
Clinical Case Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital Never smoked; does not ingest alcoholic beverages.

Clinical Case Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital Never smoked; does not ingest alcoholic beverages.
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
MICR 454L Emerging and Re-Emerging Infectious Diseases Lecture 7: M. tuberculosis Dr. Nancy McQueen & Dr. Edith Porter.

MICR 454L Emerging and Re-Emerging Infectious Diseases Lecture 7: M. tuberculosis Dr. Nancy McQueen & Dr. Edith Porter.
Diagnosis and Management of TB John Yates Consultant Infectious Diseases.

Diagnosis and Management of TB John Yates Consultant Infectious Diseases.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated 10-15 million persons.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Introduction to Tuberculosis

Introduction to Tuberculosis
MDR/XDR Tuberculosis and Atypical Mycobacterial Disease MDR/XDR Tuberculosis and Atypical Mycobacterial Disease Increasing Role for Surgery, Relearning.

MDR/XDR Tuberculosis and Atypical Mycobacterial Disease MDR/XDR Tuberculosis and Atypical Mycobacterial Disease Increasing Role for Surgery, Relearning.
Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.

Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.
Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February 2015 - Yerevan New treatments and approaches.

Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February Yerevan New treatments and approaches.
Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.

Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.
Tuberculosis: What you need to know!

Tuberculosis: What you need to know!
Antimycobacterial drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences.

Antimycobacterial drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences.
PRE-EXTENSIVELY DRUG RESISTANT (XDR) TB IN WISCONSIN  Marathon County  Population 134,700  1,545 square miles  Marathon County Health Department 

PRE-EXTENSIVELY DRUG RESISTANT (XDR) TB IN WISCONSIN  Marathon County  Population 134,700  1,545 square miles  Marathon County Health Department 

Similar presentations

Ads by Google